VivoSeq
Infectious Disease

Whooping Cough

3

Pipeline Programs↗

0

Active Trials↗

2

Companies Involved↗

Whooping Cough is an early-stage landscape with 3 programs across 2 companies. The most active players are Azurity Pharmaceuticals, Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. 3 therapies are approved.

Intelligence

Pipeline Metrics

Competitive Density

21/100

Pipeline Velocity

0/100

Mech. Concentration

100/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

A

Azurity Pharmaceuticals

1 program

ApprovedP

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

1 program

Approved

Pipeline

Programs by Phase

Analysis

Modality Breakdown

4programs
Small molecule250%
Vaccine250%

Modality classified for 100% of 4 pipeline programs.

Analysis

Trial Status

2

clinical trials

Unknown status1 · 50%
Completed1 · 50%

Clinical Trials

Trial Activity

Optimising the Timing of Whooping Cough Immunisation in MUMs
Unknown status·SSt George's, University of London·Phase 4·NCT03908164·354 enrolled
A Study Exploring Whooping Cough Protection in Children and Adults
Completed·UUniversity of Oxford·Phase 4·NCT03697798·122 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)